To identify drugs that could enhance the apoptotic effect of BCL-2/BCL-XL inhibition, while still preserving MYC-dependence, we analyzed the effect of ABT-737 in combinations with small-molecules that target cancer survival pathways (Fig. 2a). This evidence concerns the gene MYC and cancer.